The Novartis Institutes for Biomedical Research, Pfizer’s Centers for Therapeutic Innovation, GSK's Centres for Excellence in External Discovery (Working Papers) #openinnovation #opensource #drugdiscovery

Open source drug discovery is increasingly being sought as a solution for managing product development complexities. Three drivers encouraging the use of the open source strategy include: upstream knowledge-based complexities associated with complementary assets, technological complexities given the scale of research and interdependencies between disciplines and downstream commercialization complexities. While literature currently discusses the need for open source strategies

Applying the Lessons of the Past to the Challenges of COVID-19 Repurposing has the objective of targeting existing drugs and failed, abandoned, or yet-to-be-pursued clinical candidates to new disease areas. The open-source model permits for the sharing of data, resources, compounds, clinical molecules, small libraries, and screening platforms to cost-effectively advance old drugs and/or candid ates into clinical re-development. Clearly, at the core of drug-repurposing activit